SCHEMBL2980992

SCHEMBL2980992

Cc1ccc(C(=O)c2c(C)n(-c3ccc(COC4(OC=O)CCC4)cc3)c3ccccc23)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.43
USP14 P54578 6/20 0.41
MAPT P10636 3/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 2/20 0.41
POLB P06746 1/20 0.40
TP53 P04637 1/20 0.38
HDAC6 Q9UBN7 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
PKM P14618 1/20 0.36
HPGD P15428 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 1/20 0.36
HSD17B10 Q99714 1/20 0.36
AGTR1 P30556 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2980990 0.86 RORC (0.46) RORCUSP14MAPTKDM4EGAA
SCHEMBL2984839 0.83 RORC (0.47) RORCUSP14MAPTKDM4EGAA
SCHEMBL2974884 0.83 KMT2A (0.44) RORCUSP14MAPTKDM4EGAA
SCHEMBL2980581 0.83 RORC (0.45) RORCUSP14MAPTKDM4EGAA
SCHEMBL2978432 0.78 RORC (0.56) RORCUSP14MAPTKDM4EGAA
SCHEMBL2984681 0.77 RORC (0.51) RORCUSP14MAPTKDM4EGAA
SCHEMBL2983398 0.76 RORC (0.54) RORCUSP14MAPTKDM4EGAA
SCHEMBL2978547 0.75 RORC (0.49) RORCUSP14MAPTKDM4EGAA
SCHEMBL2982062 0.75 RORC (0.49) RORCUSP14MAPTKDM4EGAA
SCHEMBL2980941 0.73 SMN1; SMN2 (0.54) RORCMAPTKDM4EGAATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100286144-A1 HETEROARYL DERIVATIVES TAKAHASHI YOKO 2010-11-11 US disclosed
US-7781479-B2 Heteroaryl derivatives DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2010-08-24 US disclosed
US-20080167306-A1 Novel Heteroaryl Derivative DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2008-07-10 US disclosed
EP-1837329-A1 NOVEL HETEROARYL DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2007-09-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286144-A1 HETEROARYL DERIVATIVES GPR119, SLC2A1, SLC2A4 RORC 1515/4885USP14 3130/4885MAPT 4724/4885
US-20080167306-A1 Novel Heteroaryl Derivative GPR119, SLC2A4, SLC5A2 RORC 1977/4885USP14 2763/4885MAPT 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.